For more than half a century, the biological blueprint for how the human body stores and releases sugar was considered a settled matter. Textbooks taught a straightforward story: excess glucose is converted into glycogen—a complex carbohydrate stored primarily in the liver and muscles—and is broken down via a well-understood set of enzymatic triggers when the body needs energy.
However, a groundbreaking study published in Nature has revealed that this blueprint was incomplete. Researchers at the Walter and Eliza Hall Institute of Medical Research (WEHI) have discovered a “hidden” regulatory mechanism involving a protein called ubiquitin, which can directly attach to glycogen to control its levels. The discovery effectively rewrites a fundamental rule of biology, suggesting that the body has a secondary, “on-demand” system for managing stored sugar that has remained invisible to science until now.
As a physician, I find this distinction critical. While most current diabetes treatments focus on managing blood glucose levels or modulating hormones to influence how that glucose is handled, this discovery targets the storage depot itself. By identifying a way to directly regulate glycogen, scientists have uncovered a potential “straight-to-the-source” approach for treating a spectrum of metabolic diseases, from common conditions like type 2 diabetes and heart disease to rare, devastating genetic disorders.
The Molecular “Tag” That Changes Everything
To understand the magnitude of this find, one must first understand ubiquitin. In the world of cellular biology, ubiquitin has long been known as the cell’s “recycling tag.” Its primary job is to attach to damaged or unnecessary proteins, marking them for destruction by the cell’s disposal system. Because ubiquitin is a protein, scientists assumed it only interacted with other proteins.
The WEHI team, led by Professor David Komander and Dr. Simon Cobbold, discovered that ubiquitin is far more versatile than previously believed. They found that it can also attach to non-protein molecules, specifically glycogen—a sugar. Here’s a biological anomaly. it is akin to discovering a tool designed exclusively for metalwork suddenly being used to shape glass.
The researchers observed this process in both animal models and human cells. In a pivotal experiment using mice, the team tracked glycogen levels during cycles of feeding and fasting. They found that as the mice entered a fasting state and their glycogen stores depleted, the presence of ubiquitin “tags” on the remaining glycogen surged. This suggests that ubiquitin doesn’t just mark glycogen for removal; it actively helps regulate the breakdown of sugar when the body requires immediate energy.
Beyond Hormones: A Direct Path to Sugar Control
The medical community is currently witnessing a revolution in metabolic health, driven largely by GLP-1 receptor agonists like Ozempic and Wegovy. These drugs are transformative, but they work indirectly by mimicking hormones that regulate appetite and insulin secretion.
The WEHI discovery offers a fundamentally different strategy. While hormonal regulation tells the body how to handle sugar, the ubiquitin pathway may allow clinicians to target the glycogen molecule itself. This is particularly significant for patients suffering from Glycogen Storage Diseases (GSD), a group of rare inherited disorders where the body cannot properly produce or break down glycogen, leading to toxic buildup in the liver and heart.
For many GSD patients, there are currently no effective treatments because there has been no way to directly “clear” the excess sugar buildup. The ability to induce glycogen ubiquitination—essentially tagging the excess sugar for removal—could provide a first-of-its-kind therapeutic intervention for these rare diseases, as well as for the more common manifestations of glycogen accumulation seen in obesity and non-alcoholic fatty liver disease.
Unlocking the “Invisible” with NoPro-Clipping
The reason this mechanism remained hidden for 50 years is that the tools to see it simply did not exist. Ubiquitin-sugar bonds are chemically distinct from ubiquitin-protein bonds, making them invisible to standard mass-spectrometry proteomics.
To solve this, the WEHI team spent four years developing a technique called “NoPro-clipping.” This method uses a bacterial enzyme (BpJOS) to clip the ubiquitin off its non-protein substrates and then attaches a small peptide via another enzyme (Sortase A). This process converts the “invisible” sugar-ubiquitin modification into a peptide-modified species that can be detected by modern laboratory equipment.
| Approach | Mechanism | Primary Target | Clinical Application |
|---|---|---|---|
| Hormonal (e.g., GLP-1) | Indirect signaling | Insulin/Glucagon receptors | Blood glucose/Weight loss |
| Enzymatic | Metabolic catalysts | Glycogen synthase/phosphorylase | Standard glucose metabolism |
| Ubiquitin-based | Direct molecular tagging | Glycogen molecule itself | Direct glycogen reduction |
This technological leap has implications beyond diabetes. The team has already used NoPro-clipping to identify ubiquitinated metabolites like glycerol and spermine, suggesting that the “ubiquitin canvas” is far larger than previously imagined. As PhD student Marco Jochem noted, the discovery of glycogen ubiquitination may only be the “tip of the iceberg” in understanding how the body regulates its most basic chemical building blocks.
The Road to Clinical Application
Despite the excitement, the transition from a laboratory discovery to a pharmacy shelf is a long process. The current findings are based on human cell cultures and mouse models. The next critical phase involves determining whether pharmacological agents can safely and precisely trigger this ubiquitination process in humans without disrupting other essential cellular functions.
The researchers have already begun discussions with investors to move the discovery toward drug development. The goal is to create small molecules that can mimic or enhance the body’s natural ubiquitin-tagging process to reduce glycogen levels in diseased tissues.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
The next milestone for this research will be the development of targeted compounds capable of inducing glycogen ubiquitination in vivo, with early-stage preclinical trials expected to define the safety profile of this approach. Further updates on these developments are typically published via the Walter and Eliza Hall Institute and the journal Nature.
Do you think direct molecular targeting is the future of metabolic medicine? Share your thoughts in the comments or share this story with a colleague.
